Hand eruption after intravenous administration of bevacizumab.
Ruiz
V
V
Garcia-Muret
M P
MP
Alomar
A
A
D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000287:Administration, Topical; D000493:Allopurinol / Q000008:administration & dosage / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000473:pathology; D003875:Drug Eruptions / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology*; D016166:Free Radical Scavengers / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009824:Ointments; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016166:Free Radical Scavengers; D009824:Ointments; D000068258:Bevacizumab; D000493:Allopurinol